Company intelligence / Profile preview

Nogra Pharma

Ownership: Private
Development stage: Phase 3

Overview

Nogra Pharma develops new therapeutic agents targeting immune-inflammatory-mediated diseases. Its pipeline includes small molecules, mRNA therapies, and ASOs. Lead programs have reached up to Phase III clinical trials in indications like Crohn’s disease and acneiform eruptions. The company partners extensively with academic institutions for early-stage research and with pharma/biotech companies for late-stage development and commercialization.

Therapeutic areas: GastroenterologyDermatologyImmunology
Modalities: small moleculesmRNAantisense oligonucleotides (ASO)
Industry: Biotech

Drug pipeline

1 asset

NPD-0614

Preclinical

Partnerships

Torii Pharmaceutical Co., Ltd. (exclusive Japanese rights for Mongersen)Universities/research institutes globally

Beyond the preview

Go deeper on Nogra Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nogra Pharma.

Explore the full profile